Abstract:Abstract Background Proteins containing the Jumonji C (JmjC) domain participated in tumorigenesis and cancer progression. However, the mechanisms underlying this effect are still poorly understood. Our objective was to investigate the role of Jumonji and the AT‐rich interaction domain‐containing 2 (JARID2) — a JmjC family protein — in breast cancer, as well as its latent association with obesity. Methods Immunohistochemistry, The Cancer Genome Atlas, Gene Expression Omnibus, and other databases were used to analyze the expression of JARID2 in breast cancer cells. Growth curve, 5‐ethynyl‐2‐deoxyuridine (EdU), colony formation, and cell invasion experiments were used to detect whether JARID2 affected breast cancer cell proliferation and invasion. Spheroidization‐based experiments and xenotumor transplantation in NOD/SCID mice were used to examine the association between JARID2 and breast cancer stemness. RNA‐sequencing, Kyoto Encyclopedia of Genes and Genomes, and Gene Set Enrichment Analysis were used to identify the cell processes in which JARID2 participates. Immunoaffinity purification and silver staining mass spectrometry were conducted to search for proteins that might interact with JARID2. The results were further verified using co‐immunoprecipitation and glutathione S‐transferase (GST) pull‐down experiments. Using chromatin immunoprecipitation (ChIP) sequencing, we sought the target genes that JARID2 and metastasis‐associated protein 1 (MTA1) jointly regulated; the results were validated by ChIP‐PCR, quantitative ChIP (qChIP) and ChIP‐reChIP assays. A coculture experiment was used to explore the interactions between breast cancer cells and adipocytes. Results In this study, we found that JARID2 was highly expressed in multiple types of cancer including breast cancer. JARID2 promoted glycolysis, lipid metabolism, proliferation, invasion, and stemness of breast cancer cells. Furthermore, JARID2 physically interacted with the nucleosome remodeling and deacetylase (NuRD) complex, transcriptionally repressing a series of tumor suppressor genes such as BRCA2 DNA repair associated ( BRCA2 ), RB transcriptional corepressor 1 ( RB1 ), and inositol polyphosphate‐4‐phosphatase type II B ( INPP4B ). Additionally, JARID2 expression was regulated by the obesity‐associated adipokine leptin via Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway in the breast cancer microenvironment. Analysis of various online databases also indicated that JARID2/MTA1 was associated with a poor prognosis of breast cancer. Conclusion Our data indicated that JARID2 promoted breast tumorigenesis and development, confirming JARID2 as a target for cancer treatment.

Jumonji and AT-Rich Interacting Domain 2 (JARID2) exhibits a tumor-suppressive role in Oral Squamous Cell Carcinoma by modulating tumor progression and metastasis

JARID2, a novel regulatory factor, promotes cell proliferation, migration, and invasion in oral squamous cell carcinoma

JARID2 coordinates with the NuRD complex to facilitate breast tumorigenesis through response to adipocyte‐derived leptin

JARID1B promotes colorectal cancer proliferation and Wnt/β-catenin signaling via decreasing CDX2 level

The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ)

Splicing Factor ESRP1 Derived Circ_0068162 Promotes the Progression of Oral Squamous Cell Carcinoma Via the Mir-186/Jag Axis.

EHMT2 Suppresses ARRB1 Transcription and Activates the Hedgehog Signaling to Promote Malignant Phenotype and Stem Cell Property in Oral Squamous Cell Carcinoma

Joint detection of claudin‐1 and junctional adhesion molecule‐A as a therapeutic target in oral epithelial dysplasia and oral squamous cell carcinoma

Orosomucoid 2 Inhibits Tumor Metastasis and is Upregulated by CCAAT/enhancer Binding Protein Β in Hepatocellular Carcinomas

Binding of the JmjC Demethylase JARID1B to LSD1/NuRD Suppresses Angiogenesis and Metastasis in Breast Cancer Cells by Repressing Chemokine CCL14.

Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1-mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma.

Jmjd2c maintains the ALDHbri+ cancer stemness with transcription factor SOX2 in lung squamous cell carcinoma

JMJD2A Contributes to Breast Cancer Progression Through Transcriptional Repression of the Tumor Suppressor ARHI

High expression of disabled homolog 2-interacting protein contributes to tumor development and proliferation in cutaneous squamous cell carcinoma

JAM2 is a prognostic biomarker and inhibits proliferation, metastasis and epithelial–mesenchymal transition in lung adenocarcinoma

DDB2 regulates Epithelial-to-Mesenchymal Transition (EMT) in Oral/Head and Neck Squamous Cell Carcinoma

Serine hydroxymethyltransferase 2 (SHMT2) potentiates the aggressive process of oral squamous cell carcinoma by binding to interleukin enhancer-binding factor 2 (ILF2)

JOSD1 promotes proliferation and chemoresistance of head and neck squamous cell carcinoma under the epigenetic regulation of BRD4

Effects of Sirna-Mediated Knockdown of Jumonji Domain Containing 2A on Proliferation, Migration and Invasion of the Human Breast Cancer Cell Line MCF-7.

Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer

Downregulation of SLC3A2 mediates immune evasion and accelerates metastasis in oral squamous cell carcinoma